Company UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for UroGen Pharma Ltd.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-02 EDT			5-day change	1st Jan Change
14.22 ^USD	-1.25%		+2.89%	-5.20%

04-15	UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	MT
04-03	UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	MT

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Number of employees: 200

USD in Million	2022	Weight	2023	Weight	Delta
RTGel Reverse-Thermal Hydrogel 100.0 %	64	100.0 %	83	100.0 %	+28.52%

USD in Million	2022	Weight	2023	Weight	Delta
Israel 100.0 %	64	100.0 %	83	100.0 %	+28.52%

Managers	Title	Age	Since
Elizabeth Barrett CEO	Chief Executive Officer	62	19-01-02
Dong Kim DFI	Director of Finance/CFO	47	21-07-31
Jason Smith CMP	Compliance Officer	52	20-09-08
Marina Konorty CTO	Chief Tech/Sci/R&D Officer	-	10-12-31
Moran Mieron CTO	Chief Tech/Sci/R&D Officer	52	-
Mark Schoenberg CTO	Chief Tech/Sci/R&D Officer	66	16-02-08
Vincent I. Perrone IRC	Investor Relations Contact	-	21-12-31
Polly Murphy PRN	Corporate Officer/Principal	59	20-09-08
Jeff Bova PRN	Corporate Officer/Principal	-	16-12-31
James Ottinger LAW	General Counsel	-	17-09-30

Members of the board	Title	Age	Since
Arie Belldegrun CHM	Chairman	74	12-09-30
Cynthia Butitta BRD	Director/Board Member	70	17-09-30
Fred Cohen BRD	Director/Board Member	67	17-05-15
Stuart Holden BRD	Director/Board Member	82	15-11-30
Elizabeth Barrett CEO	Chief Executive Officer	62	19-01-02
James Robinson BRD	Director/Board Member	54	23-07-24
Daniel Wildman BRD	Director/Board Member	68	22-11-07
Leana Wen BRD	Director/Board Member	41	22-09-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,130,121	32,257,075 ( 89.28 %)	0	89.28 %

Name	Equities	%	Valuation
RA Capital Management LP 9.036 %	3,083,430	9.036 %	46 M $
Jeffrey Robert Jay 7.680 %	2,620,545	7.680 %	39 M $
MENORA MIVTACHIM HOLDINGS LTD 6.749 %	2,303,031	6.749 %	35 M $
Menora Mivtachim Provident Funds Ltd. 5.951 %	2,030,563	5.951 %	30 M $
RTW Investments LP 5.061 %	1,726,808	5.061 %	26 M $
BlackRock Advisors LLC 4.817 %	1,643,692	4.817 %	25 M $
Monograph, Inc. 4.499 %	1,535,169	4.499 %	23 M $
Pontifax Management Co. Ltd. 4.353 %	1,485,169	4.353 %	22 M $
Moshe Arkin 4.013 %	1,369,315	4.013 %	21 M $
Crédit Suisse Fund Management SA 3.517 %	1,200,000	3.517 %	18 M $

UroGen Pharma Ltd.

400 Alexander Park Drive 4th floor

08540, Princeton

+(646) 768-9780

http://www.urogen.com

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.26 USD

Average target price

38.5 USD

Spread / Average Target

+169.99%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
UROGEN PHARMA LTD.	-5.20%	487M
VERTEX PHARMACEUTICALS INCORPORATED	-1.65%	103B
REGENERON PHARMACEUTICALS, INC.	+6.75%	101B
ARGENX SE	+6.90%	23.07B
BIONTECH SE	-12.60%	22.23B
GENMAB A/S	-5.43%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.17%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.12%	14.07B
SAREPTA THERAPEUTICS, INC.	+35.47%	12.35B

Bio Therapeutic Drugs